Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
CN Stock MarketDetailed Quotes
688710 Shanghai InnoStar Bio-tech
- 30.57
- -1.19-3.75%
Market Closed Apr 30 15:00 CST
4.31BMarket Cap44.76P/E (TTM)
30.80High29.10Low15.69KlotVolume29.10Open31.76Pre Close47.33MTurnover5.57%Turnover Ratio29.17P/E (Static)140.98MShares50.1352wk High1.80P/B861.95MFloat Cap22.5252wk Low38.11Limit Up28.20MShs Float50.13Historical High25.41Limit Down5.35%Amplitude22.52Historical Low--Dividend TTM30.16Avg Price7.49KlotAsk--Div YieldTTM100Lot Size7.84KlotBid
About Shanghai InnoStar Bio-tech Company
The company was founded in 2010 and is a holding subsidiary of China Pharmaceutical Industry Research Institute Co., Ltd., a subsidiary of Sinopharm Group. Adhering to the core values of “scientific leadership, quality first, honesty and dedication, and win-win cooperation”, we take science as the lead and customer as the center. The company is a comprehensive research and development service (CRO) enterprise specializing in providing biomedical non-clinical research services. The company's main products are early pharmacogenicity evaluation, non-clinical research, clinical testing and translational research of biomedicines. Corporate honors: In 2024, the company won many honors such as “Central Advanced Collective Title”, “Shanghai Enterprise Technology Center”, and “Jiangsu Province Modern Service Industry High Quality Development Leading Enterprise”. In the industry sector, the company has successively won honors such as “Asia Pacific Cell and Gene Therapy Industry Star Best CRO”, “Top 20 Chinese Pharmaceutical CRO Companies”, “ADC New Infrastructure Pioneer Enterprise”, “CGT CRO Cooperation Star Award”, “Top 10 Local CXO Service Excellent Suppliers for Bioinnovative Drugs”, and innovative SMEs in Shenzhen.
Company Profile
Short Name-A益诺思生物
Company NameShanghai InnoStar Bio-tech Co., Ltd.
Listing DateSep 3, 2024
Issue Price19.06
Shares Offered35.24M share(s)
FoundedMay 12, 2010
Chairmanshuyuan wei
Legal Representativeyan chang
General Manageryan chang
Secretaryyan li
Employees1085
ProvinceShang Hai Shi
Phone021-50801259
Office Address199 Guo Shoujing Road, China (Shanghai) Pilot Free Trade Zone
Zip Code201203
Registered AddressRoom 106, 199 Guo Shoujing Road, China (Shanghai) Pilot Free Trade Zone
Fax021-50801259
Emailbo@innostar.cn
Websitehttps://www.innostar.cn/
Business License91310000555907546T
BusinessThe issuer is a comprehensive research and development service (CRO) enterprise specializing in providing biomedical non-clinical research services. As one of the earliest domestic companies that also has NMPA GLP certification, OECD GLP certification, and US FDA GLP inspection, it is in line with international standards, has competitive international service capabilities within the industry, and provides a full range of new drug research services that meet domestic and international declaration standards for pharmaceutical companies and research institutions around the world. The company's services mainly cover the three major segments of biomedicine early pharmacogenicity evaluation, non-clinical research, and clinical testing and translational research. Among them, the non-clinical research section specifically includes non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamics research.
Company Executives
- Name
- Position
- Salary
- shuyuan wei
- Chairman, Directors
- --
- yan chang
- Directors, General Manager
- 1.78M
- weiping zhuang
- Directors
- --
- yong zhang
- Directors
- --
- weigen lu
- Directors
- --
- shengcai li
- Independent Directors
- 80.00K
- guoqin fan
- Independent Directors, Member of the Strategic Planning Committee, Nomination Committee Members, Chairman of the Remuneration and Assessment Committee
- --
- rong shao
- Independent Directors
- 80.00K
- yan li
- Board Secretary
- 721.70K
- xue bai
- Securities Affairs Representative
- --
- li gao
- Chairman of the Supervisory Board, Auditors
- --
- taotao ying
- Auditors
- --
- hua li
- Deputy General Manager
- 963.80K
- xiaohong gao
- Chief Financial Officer
- 1.18M
- wenjun yang
- Employee Supervisors
- 410.70K
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts